Vigilant cells
US9040676B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 11, 2004 |
| Grant date | May 26, 2015 |
| Priority date | — |
| Expiry date | Jun 15, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2830/85
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention concerns a system for modulating tissue physiology, for example, to prevent or reverse tissue damage caused by disease. The system utilizes vigilant cells that include stable vectors containing a gene switch/biosensor and a gene amplification system. The vectors allow expression of a transgene (such as a cardioprotective gene) in the vigilant cells to be regulated in response to a physiological signal, to be switched on or off, and to provide sufficient levels of the transgene product to achieve a desired result, e.g., prevention or reversal of myocardial cell damage. In addition to myocardial infarction, the vectors can be used to treat cells in a number of other disease states, including diabetes, cancer, stroke, and atherosclerosis. These approaches to stem cell-based gene therapy provide a novel strategy not only for treatment but for prevention of cell destruction.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.